Peptio

Sources

Every study, trial record and regulatory document cited anywhere on this site, listed with its study design and the species it was conducted in.

75 sources catalogued.

  1. A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery. ClinicalTrials.gov. 2026.

    case serieshumann = 40View source

  2. A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye (ARISE-3). ClinicalTrials.gov. 2026.

    rcthumann = 700View source

  3. A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye: ARISE-2. ClinicalTrials.gov. 2026.

    rcthumann = 601View source

  4. A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Sequential Dose-Escalation Study of TB-500 (Thymosin Beta 4 17-23 Fragment) in Adults With Stable Atherosclerotic Cardiovascular Disease to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Cardiovascular Biomarkers. ClinicalTrials.gov. 2026.

    rcthumann = 80View source

  5. A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-4). ClinicalTrials.gov. 2026.

    rcthumann = 445View source

  6. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity (TRIUMPH-5). ClinicalTrials.gov. 2026.

    rcthumann = 800View source

  7. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (TRIUMPH-Outcomes). ClinicalTrials.gov. 2026.

    rcthumann = 10000View source

  8. A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease (TRIUMPH-3). ClinicalTrials.gov. 2026.

    rcthumann = 1946View source

  9. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain. ClinicalTrials.gov. 2026.

    rcthumann = 120View source

  10. A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO). ClinicalTrials.gov. 2026.

    guidancen aView source

  11. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  12. Piatkowski T et al. Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia. Drug and Alcohol Review. 2026.

    in vitron an = 3View source

  13. Laroche ML, Géniaux H, Jardou M. Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. European Journal of Clinical Pharmacology. 2026.

    case serieshumanView source

  14. Biçer O et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery. 2026.

    animalratn = 32View source

  15. Bajaj HS et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet. 2026.

    rcthumann = 537View source

  16. FAERS adverse event reports for BPC-157, retrieved and summarised by FDA's Office of Surveillance and Epidemiology (database search through December 4, 2025), in the Pharmacy Compounding Advisory Committee briefing document. U.S. Food and Drug Administration. 2026.

    case reporthumann = 3View source

  17. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026: Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 (Free Base) and BPC-157 Acetate) for Inclusion on the 503A Bulk Drug Substances List. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  18. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026: Evaluation of TB-500-related Bulk Drug Substances (TB-500 (Free Base) and TB-500 acetate) for Inclusion on the 503A Bulk Drug Substances List. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  19. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  20. FDA Global Substance Registration System, Retatrutide, UNII NOP2Y096GV. U.S. Food and Drug Administration, precisionFDA GSRS. 2026.

    guidancen aView source

  21. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  22. Impact of BPC-157 on Recovery From Rotator Cuff Repair Surgery. ClinicalTrials.gov. 2026.

    rcthumann = 30View source

  23. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  24. Medicines output: medicines report (generated 2 October 2026). European Medicines Agency. 2026.

    guidancen aView source

  25. MOUNJARO (tirzepatide) injection, for subcutaneous use. Prescribing Information, revised 08/2026 (NDA 215866, S-044 and S-045). U.S. Food and Drug Administration, Drugs@FDA. 2026.

    guidancen aView source

  26. Mounjaro: EPAR, Product Information (Annex I, Summary of Product Characteristics). European Medicines Agency. 2026.

    guidancen aView source

  27. NDA 215866/S-044 and S-045 supplement approval letter, Mounjaro (tirzepatide), major adverse cardiovascular events indication, August 27, 2026. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  28. Pre-approval Expanded Access of Retatrutide (LY3437943). ClinicalTrials.gov. 2026.

    guidancen aView source

  29. Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. The Lancet. 2026.

    rcthumann = 1152View source

  30. Jastreboff AM et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. 2026.

    rcthumann = 2339View source

  31. The Prohibited List, World Anti-Doping Agency. World Anti-Doping Agency. 2026.

    guidancen aView source

  32. Warning Letter, Gram Peptides, MARCS-CMS 721806, March 31, 2026. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  33. Warning Letter, Royal Peptides LLC, MARCS-CMS 734884, August 24, 2026. U.S. Food and Drug Administration. 2026.

    guidancen aView source

  34. ZEPBOUND (tirzepatide) injection, for subcutaneous use. Prescribing Information, revised 08/2026 (NDA 217806, S-041). U.S. Food and Drug Administration, Drugs@FDA. 2026.

    guidancen aView source

  35. Nicholls SJ et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.. The New England Journal of Medicine. 2025.

    rcthumann = 13299View source

  36. Hannon TS et al. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial.. The Lancet. 2025.

    rcthumann = 99View source

  37. Vasireddi N et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025.

    systematic reviewother animalView source

  38. Jozwiak M et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals. 2025.

    narrative reviewn aView source

  39. NDA 215866/S-039 supplement approval letter, Mounjaro (tirzepatide), pediatric patients 10 years and older with type 2 diabetes, December 19, 2025. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  40. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025.

    case reporthumann = 2View source

  41. Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.. The New England Journal of Medicine. 2025.

    rcthumann = 751View source

  42. Packer M et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.. The New England Journal of Medicine. 2025.

    rcthumann = 731View source

  43. Warning Letter, USApeptide.com, MARCS-CMS 696885, February 26, 2025. U.S. Food and Drug Administration. 2025.

    guidancen aView source

  44. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.. JAMA. 2024.

    rcthumann = 670View source

  45. Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound), December 19, 2024. U.S. Food and Drug Administration. 2024.

    guidancen aView source

  46. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine. 2024.

    case serieshumann = 12View source

  47. FDA Roundup: December 17, 2024. U.S. Food and Drug Administration. 2024.

    guidancen aView source

  48. NDA 217806 S-013 supplement approval letter, Zepbound (tirzepatide), obstructive sleep apnea indication, December 20, 2024. U.S. Food and Drug Administration. 2024.

    guidancen aView source

  49. Rahaman KA et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences. 2024.

    animalratView source

  50. Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.. The New England Journal of Medicine. 2024.

    rcthumann = 469View source

  51. Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024.

    rcthumann = 98View source

  52. NDA 217806 approval letter, Zepbound (tirzepatide) injection, November 8, 2023. U.S. Food and Drug Administration. 2023.

    guidancen aView source

  53. Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023.

    rcthumann = 281View source

  54. Delcourt V et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Testing and Analysis. 2023.

    in vitron aView source

  55. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.. The Lancet. 2023.

    rcthumann = 938View source

  56. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine. 2023.

    rcthumann = 338View source

  57. NDA 215866 approval letter, Mounjaro (tirzepatide) injection, May 13, 2022. U.S. Food and Drug Administration. 2022.

    guidancen aView source

  58. He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology. 2022.

    animalratView source

  59. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity.. The New England Journal of Medicine. 2022.

    rcthumann = 2539View source

  60. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.. The Lancet. 2021.

    rcthumann = 478View source

  61. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021.

    case serieshumann = 17View source

  62. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.. The New England Journal of Medicine. 2021.

    rcthumann = 1879View source

  63. Xu C et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology. 2020.

    animalratView source

  64. Shah R, Reyes-Gordillo K, Rojkind M. Thymosin beta 4 inhibits PDGF-BB induced activation, proliferation, and migration of human hepatic stellate cells via its actin-binding domain. Expert Opinion on Biological Therapy. 2018.

    in vitrocell lineView source

  65. Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017.

    in vitrocell lineView source

  66. Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157, a Penta-deca-peptide From Gastric Source. ClinicalTrials.gov. 2015.

    rcthumann = 42View source

  67. Chang CH et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014.

    in vitroratView source

  68. Ho ENM et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta 4, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of Chromatography A. 2012.

    animalother animalView source

  69. Esposito S et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis. 2012.

    in vitron aView source

  70. Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011.

    in vitroratView source

  71. Sosne G et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB Journal. 2010.

    narrative reviewn aView source

  72. Cerovecki T et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research. 2010.

    animalratView source

  73. Novinscak T et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surgery Today. 2008.

    animalratView source

  74. Staresinic M et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003.

    animalratView source

  75. Philp D et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration. 2003.

    animalmouseView source